Combined Anti-PD-1/PD-L1 and Anti-angiogenic Therapy: An Emerging Direction for Future NSCLC Treatment

Mingtai Li, Zhiqing Wu, Xin Zheng, Yanhong Zhu, Yuxuan Wu, Jiaxin He, Xin Wu, Jingtong Xu, Yinyin Qin

Open source

DOI
10.1007/s11864-026-01412-1
Published
2026-09-04
Container
Current Treatment Options in Oncology
Publisher
Springer Science and Business Media LLC
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s11864-026-01412-1,
  title = {Combined Anti-PD-1/PD-L1 and Anti-angiogenic Therapy: An Emerging Direction for Future NSCLC Treatment},
  author = {Mingtai Li and Zhiqing Wu and Xin Zheng and Yanhong Zhu and Yuxuan Wu and Jiaxin He and Xin Wu and Jingtong Xu and Yinyin Qin},
  year = {2026},
  journal = {Current Treatment Options in Oncology},
  doi = {10.1007/s11864-026-01412-1},
  url = {https://doi.org/10.1007/s11864-026-01412-1}
}

RIS

TY  - JOUR
TI  - Combined Anti-PD-1/PD-L1 and Anti-angiogenic Therapy: An Emerging Direction for Future NSCLC Treatment
AU  - Mingtai Li
AU  - Zhiqing Wu
AU  - Xin Zheng
AU  - Yanhong Zhu
AU  - Yuxuan Wu
AU  - Jiaxin He
AU  - Xin Wu
AU  - Jingtong Xu
AU  - Yinyin Qin
PY  - 2026
JO  - Current Treatment Options in Oncology
DO  - 10.1007/s11864-026-01412-1
UR  - https://doi.org/10.1007/s11864-026-01412-1
ER  - 

APA

Li, M., Wu, Z., Zheng, X., Zhu, Y., Wu, Y., He, J., Wu, X., Xu, J., & Qin, Y. (2026). Combined Anti-PD-1/PD-L1 and Anti-angiogenic Therapy: An Emerging Direction for Future NSCLC Treatment. Current Treatment Options in Oncology. https://doi.org/10.1007/s11864-026-01412-1

Source records